A detailed history of Vanguard Group Inc transactions in Black Diamond Therapeutics, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 2,318,011 shares of BDTX stock, worth $5.77 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
2,318,011
Previous 2,131,624 8.74%
Holding current value
$5.77 Million
Previous $9.93 Million 1.51%
% of portfolio
0.0%
Previous 0.0%

Shares

13 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 13, 2024

BUY
$4.2 - $6.58 $782,825 - $1.23 Million
186,387 Added 8.74%
2,318,011 $10.1 Million
Q2 2024

Aug 13, 2024

BUY
$4.65 - $7.39 $1.05 Million - $1.67 Million
226,324 Added 11.88%
2,131,624 $9.93 Million
Q1 2024

May 10, 2024

SELL
$2.67 - $5.74 $111,587 - $239,891
-41,793 Reduced 2.15%
1,905,300 $9.66 Million
Q4 2023

Feb 14, 2024

SELL
$1.77 - $3.03 $29,187 - $49,964
-16,490 Reduced 0.84%
1,947,093 $5.47 Million
Q3 2023

Nov 14, 2023

BUY
$2.87 - $4.99 $1.38 Million - $2.41 Million
482,198 Added 32.55%
1,963,583 $5.64 Million
Q2 2023

Aug 14, 2023

BUY
$1.43 - $6.18 $1.04 Million - $4.47 Million
723,800 Added 95.54%
1,481,385 $7.48 Million
Q4 2022

Feb 10, 2023

BUY
$1.27 - $2.51 $618 - $1,222
487 Added 0.06%
757,585 $1.36 Million
Q3 2022

Nov 14, 2022

BUY
$1.68 - $4.01 $154,796 - $369,485
92,141 Added 13.86%
757,098 $1.28 Million
Q2 2022

Aug 12, 2022

SELL
$1.5 - $3.63 $17,595 - $42,579
-11,730 Reduced 1.73%
664,957 $1.64 Million
Q1 2022

May 13, 2022

SELL
$2.66 - $5.61 $899,356 - $1.9 Million
-338,104 Reduced 33.32%
676,687 $1.88 Million
Q4 2021

Feb 14, 2022

SELL
$5.18 - $8.48 $440,465 - $721,071
-85,032 Reduced 7.73%
1,014,791 $5.41 Million
Q3 2021

Nov 12, 2021

SELL
$8.46 - $12.42 $3.9 Million - $5.72 Million
-460,636 Reduced 29.52%
1,099,823 $9.3 Million
Q2 2021

Aug 13, 2021

BUY
$12.19 - $28.17 $19 Million - $44 Million
1,560,459 New
1,560,459 $19 Million

Others Institutions Holding BDTX

About Black Diamond Therapeutics, Inc.


  • Ticker BDTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 36,339,500
  • Market Cap $90.5M
  • Description
  • Black Diamond Therapeutics, Inc., a biotechnology company, discover, develops, and commercializes medicines for patient with genetically defined tumors. It develops BDTX-189, an irreversible small molecule inhibitor that is designed to targets oncogenic proteins defined by the non-canonical epidermal growth factor receptor (EGFR) and human epide...
More about BDTX
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.